|Day Low/High||1.71 / 1.92|
|52 Wk Low/High||1.56 / 6.32|
These stocks trading for less than $10 a share are within range of breaking out and trading higher from current levels.
Clinically validated BREVAGenplus(R) more accurately identifies sporadic breast cancer risk
Personalized, Genetically-Based Test Enables Physicians to Tailor Breast Cancer Screening and Reduction Services Based on Individual Risk
Shares of Genetic Technologies Ltd. (GENE) rose Monday after the molecular diagnostics company announced that two new breast health centers will start to offer BREVAGenplus®.
Findings presented at the 2014 San Antonio Breast Cancer Symposium
Gene Technologies (GENE) shares are climbing after reporting a rise in sales of its cheek swab breast caner test, BREVAGen.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.